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ABSTRACT
Objective  This 9-month open-label extension of the 
Circadian Administration of Prednisone in Rheumatoid 
Arthritis Study (CAPRA 1) investigated the long-term 
safety and efﬁ  cacy of prednisone chronotherapy with 
a novel modiﬁ  ed-release (MR) prednisone for up to 12 
months.
Methods  Of 288 patients with rheumatoid arthritis 
originally randomised to MR or immediate-release 
(IR) prednisone, 249 continued with prednisone 
chronotherapy (2–10 mg/day) in the 9-month open-label 
extension. Duration of morning stiffness of the joints 
(MS), disease activity scores (DAS28), American College 
of Rheumatology (ACR20) responses and plasma levels of 
interleukin 6 (IL-6) were assessed. Safety was analysed 
from adverse event reports and laboratory investigations.
Results  During the 3-month double-blind phase, patients 
in the MR group achieved a reduction in MS of 33.1% 
while no change was observed in the IR group. After 
6 months of treatment, MS was reduced in the IR/MR 
group by 54% and in the MR/MR group by 56%. MS 
reduction after 12 months was 45% (IR/MR group) and 
55% (MR/MR group). Plasma levels of IL-6 declined on 
MR treatment. DAS28 was reduced from 5.8 to 4.8 (MR/
MR group) and 4.9 (IR/MR group), respectively. 37% of 
the 219 patients who completed the 12-month study 
achieved improvement according to the ACR20 criteria. 
Adverse events did not differ from the known proﬁ  le of 
low-dose prednisone.
Conclusions  Prednisone chronotherapy with the 
MR tablet was safe and well tolerated and provided a 
sustained improvement which resulted in a better beneﬁ  t 
to risk ratio of low-dose glucocorticoid treatment for at 
least 12 months.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂ  amma-
tory disease that can cause joint damage, extra-
articular manifestations and disability. Symptoms 
include fatigue, joint pain and swelling and morn-
ing stiffness of the joints (MS), reducing quality of 
life and the ability to remain gainfully employed.1
Although accepted classiﬁ  cation and remission 
criteria for RA include MS,2 3 this symptom remains 
neglected in clinical studies. MS was found to be 
strongly associated with pain and functional inca-
pacity and, to a lesser degree, with swollen and ten-
der joint counts and acute phase responses.1 Severe 
MS in the early course of RA was identiﬁ  ed  as 
having a high impact on patients’ early retirement 
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from working life and, therefore, greater attention 
should be paid to effective treatments of MS.1
The symptoms of RA show pronounced circa-
dian rhythms with the highest severity in the early 
morning. The redistribution of interstitial ﬂ  uids 
while asleep and circadian changes in synovial ﬂ  uid 
composition may contribute to stiffness, because 
oedema of the synovium and the periarticular struc-
tures interferes with joint biomechanics.4 Many 
studies on circadian rhythms in RA have reported 
the temporal relationship between raised levels 
of proinﬂ   ammatory cytokines, insufﬁ  cient  anti-
inﬂ  ammatory protection and RA symptoms.5–10 A 
recent study investigating overnight variations in 
cytokine and cortisol concentrations in 16 patients 
with RA reported that nocturnal interleukin 6 (IL-6) 
levels start to increase approximately 3 h before 
increases in cortisol and peak at approximately 
08:00 h, 40 min before cortisol.11 From all these 
data, it was concluded that there must be a link 
between the overnight rise in IL-6 and the circadian 
variation in RA symptoms.
This conclusion could have important conse-
quences for dose and timing of oral glucocorticoid 
(GC) treatments. Indeed, it has previously been 
suggested that GC administration between 06:00 
and 08:00 h could be just too late as   night-time 
pathophysiological processes have already initi-
ated inﬂ  ammation.4 6 Preventing the rise in proin-
ﬂ   ammatory cytokines should therefore be more 
  efﬁ   cacious than treating the symptoms. In line 
with this thought, a modiﬁ  ed-release (MR) predni-
sone tablet was developed to optimise GC therapy 
of RA in a novel chronotherapy approach. If taken 
at bedtime, the new tablet releases prednisone 4 h 
after ingestion—that is, at approximately 02:00 h 
(Comparative bioavailability study of one new 
timed-release formulation of prednisone (5 mg 
tablet) dosed in the evening with or without food 
and a reference immediate-release formulation 
(Decortin® 5 mg tablet) dosed in the night with-
out food, after single oral dose administration 
in healthy male subjects. Clinical Study Report, 
Merck KGaA, Darmstadt, Germany, 12 December 
2003, EMR 62 215-005). The efﬁ  cacy and safety of 
this medication was investigated in a controlled 
clinical study in 288 patients with active RA 
who were previously treated with GCs, disease-
modifying antirheumatic drugs (DMARDs) and 
non-steroidal anti-inﬂ  ammatory drugs (NSAIDs).5 
During the initial double-blind treatment phase, all 
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patients either continued on immediate-release (IR) prednisone 
or were switched to prednisone chronotherapy with the novel 
MR formulation, both at their individual prestudy doses. The 
primary end point was the relative change in duration of MS 
after 12 weeks of treatment, which showed signiﬁ  cantly greater 
improvements in the prednisone chronotherapy group. The 
safety proﬁ  le did not show differences between the two treat-
ments.5 The additional beneﬁ  t of the new tablet was considered 
important for daily clinical practice.12
In this paper we report the results of using low-dose predni-
sone chronotherapy for up to 12 months.
METHODS
Patients
All patients who completed the double-blind study and did not 
develop any exclusion criteria were eligible to continue treat-
ment with MR prednisone. The study was conducted in compli-
ance with the Declaration of Helsinki at 29 centres in Germany 
and Poland. The protocol was approved by the responsible 
administrative bodies and ethics committees.
Study design
The study design, types of treatment and visit schedule are 
summarised in ﬁ   gure 1A. Before the study all patients had 
been treated with stable doses of GCs, DMARDs and NSAIDs. 
During the 3-month double-blind phase, patients received either 
IR prednisone in the morning and MR prednisone placebo in 
the evening, or IR prednisone placebo in the morning and MR 
prednisone in the evening. During the open-label extension all 
patients received MR prednisone in the evening. The study was 
performed between August 2004 and January 2007.
Procedures
The ﬁ  rst dose of open-label MR prednisone (Skye Pharma, Lyon, 
France; distributed by Merck KGaA, Darmstadt, Germany) 
was taken between 21:30 h and 22:30 h on the last day of the 
double-blind study. The starting doses for individual patients 
were equivalent to doses during the double-blind phase. Daily 
doses were composed of the appropriate number of 1 mg and 
5 mg tablets. In contrast to the requirement of stable doses 
for prednisone and DMARDs during the double-blind phase, 
Figure 1  Study design and overview of study population. (A) Study phases, treatments and visit schedule; shaded boxes, treatment with MR 
prednisone open boxes, treatment with IR prednisone. (B) Trial proﬁ  le. DB, double-blind study phase; IR, immediate-release; MR, modiﬁ  ed-release. 
*Data reported by Buttgereit et al.5
375 Patients screened
288 Randomised
130 Completed
219 Completed open phase
1 Declined to go on in
open phase
144 Assigned to
IR prednisone in the morning
144 Assigned to
 MR prednisone in the evening
14 (9.7%) withdrawn:
10 (6.9%) adverse events
  4 (2.8%) non medical reasons
23 (16.0%) Withdrawn: 
12 (8.3%) Adverse events
3 (2.1%) Other medical reasons 
8 (5.6%) Non-medical reasons
30 (12.0%) Withdrawn: 
12 (4.8%) Adverse events
6 (2.4%) Other medical reasons
12 (4.8%) Non medical reasons
251 eligible for open phase
249 Entered open phase
DB-Phase*
month 1–3
Open phase
month 4–12
121 Completed
1 Declined to go on in
open phase
B
A
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272 (94.4%) received concomitant therapy with DMARDs at 
baseline (MR group: n=133, 92.4%; IR group: n=139, 96.5%). 
These DMARDs were (in the MR and IR groups, respectively): 
methotrexate in 74% and 73% of patients; sulfasalazine in 13% 
in both groups; leﬂ  unomide in 11% and 18%; and <10% of 
patients in both groups had a combination of two DMARDs. 
Of the 249 patients in the open phase of the study, 238 (95.6%) 
received DMARDs at baseline. During the open-label extension 
three more patients (n=241) added a DMARD, increasing the 
percentage to 96.8%; 76.3% of these 241 patients were receiv-
ing methotrexate, 11.9% were receiving sulfasalazine, 14% were 
receiving leﬂ  unomide and <10% were receiving   combination 
dose changes were permitted during the open-label extension. 
During the double-blind phase, patients completed the appro-
priate pages in their diaries every morning and every evening 
before going to bed. During the open phase, completion of the 
diary pages was required every morning and every evening for 
at least 7 days immediately before each scheduled study visit. 
Requested entries included waking-up time, stiffness (yes/no), 
time of resolution of stiffness and intensity of pain during the 
day (100 mm visual analogue scale, VAS).
Additional procedures included documentation of adverse 
events (AEs), blood sampling for erythrocyte sedimentation rate 
(ESR) and C reactive protein, assessment of the disease activity 
score (DAS28, including 28 joints checked for swelling and ten-
derness), patient’s assessment of disease activity on a 100 mm 
VAS (end points 0=not active and 100=extremely active) and 
physicians’ global assessment of disease activity (5-point scale: 
asymptomatic, mild, moderate, severe, very severe). At each 
visit investigators recorded all AEs following accepted clinical 
trial guidelines and deﬁ  nitions. No checklists with predeﬁ  ned 
AEs were used.
Procedures performed at the end of the study included a 
physical examination, blood sampling for laboratory investiga-
tions and determination of IL-6 plasma concentrations. Local 
biochemistry laboratories performed ESR measurements, hae-
matology and urinalysis; all other biochemistry analyses were 
performed by Bio Analytical Research (BARC), Gent, Belgium.
Target variables
Efﬁ  cacy end points were absolute and relative reductions in MS 
duration, changes in IL-6 plasma levels, DAS28, pain intensity 
and American College of Rheumatology (ACR20) improvement. 
The safety of MR prednisone was analysed from AE reports, 
clinical biochemistry investigations and physical examinations.
Statistical analysis
MS duration was calculated from the diaries as 7-day means 
before each visit and deﬁ   ned as the difference between the 
time of resolution of stiffness and the time of awakening. This 
was expressed as absolute and relative changes from baseline 
corresponding to the start of the double-blind phase (xbase). 
Thus, MS duration was expressed as absolute changes deﬁ  ned 
as postbaseline value minus baseline value (ie, xvisit – xbase). 
Relative changes from baseline are given as 100 times the abso-
lute change under treatment divided by the baseline value (ie, 
100% × (xvisit − xbase)/xbase).
Data of the open-label phase were evaluated using descriptive 
statistics.
Although all patients were treated with MR prednisone dur-
ing the open-label extension, we describe the groups separately 
as randomised. Accordingly, groups are identiﬁ  ed as the IR/MR 
group with 9 months of treatment and the MR/MR group with 
12 months of treatment with MR prednisone.
RESULTS
Of the 288 randomised patients, 251 completed the double-blind 
phase.5 All qualiﬁ  ed for continuation with MR prednisone and 
249 patients consented to continue, 219 of whom completed 
the entire 12-month study. The patient disposition is shown in 
ﬁ  gure 1B.
Baseline demographics and main disease characteristics did 
not differ between the 288 patients starting the double-blind 
phase and the 249 patients continuing MR treatment in the 
open-label extension (table 1). Of the 288 randomised patients, 
Table 1  Patient characteristics and disease activity at baseline 
before start of the double-blind trial phase of the total study population 
(N=288) and of the group of patients continuing treatment with open-
label modiﬁ  ed-release prednisone (N=249)
 
Double-blind population 
at baseline (N=288)*
Open-label population 
at baseline (N=249)
Age (years)
  Mean (SD) 55.0 (11.2) 54.7 (11.1)
 Range 20–79 20–78
Age class (n (%))
  ≤45 years 49 (17.0) 42 (16.9)
 >45  and  ≤65 years 185 (64.2) 163 (65.5)
 >65  and  ≤75 years 49 (17.0) 41 (16.5)
  >75 years 5 (1.7) 3 (1.2)
Weight (kg)
  Mean (SD) 70.6 (14.7) 70.8 (14.8)
 Range 43–115 43–115
Gender (n (%))
  Men 41 (14.2) 33 (13.3)
  Women 247 (85.8) 216 (86.7)
Ethnic origin
  White 287 (99.7) 248 (99.6)
  Asian 1 (0.3) 1 (0.4)
Disease activity (n (%))
 Asymptomatic 0 0
  Mild 27 (9.4) 23 (9.2)
  Moderate 205 (71.2) 175 (70.3)
  Severe 56 (19.4) 51 (20.5)
   Very  severe 
(physician’s assessment)
00
Duration of MS (min)
  Mean (SD) 173.4 (114.2) 169.8 (114.4)
 Range 13–720 32–720
Pain intensity VAS (mm) 
  Mean (SD) 58.8 (15.3) 52.0 (16.14)
 Range 16–96 6–97
DAS 28
  Mean (SD) 5.9 (0.8) 5.9 (0.8)
 Range 3.3–8.1 3.3–8.1
HAQ-DI score
  Mean (SD) 1.5 (0.5) 1.5 (0.6)
 Range 0.0–2.9 0.0–2.8
Duration of RA (months)
  Mean (SD) 115.3 (92.7) 115.0 (92.5)
 Median 90.0 91.0
 Range 3–526 3–526
Previous RA treatments
  Stable dose prednisone (mg)
   Mean  (SD) 6.6  (2.2)† 6.6  (2.2)
   Range 2.0–10.0 2.0–10.0
  DMARDs (n (%)) 272 (94.4) 238 (95.6)‡
*In contrast to the previously reported baseline characteristics, data here have not been 
separated for the two randomised study groups.
†Mean prednisone doses for the two treatment groups in the double-blind phase were 
6.5 mg for modiﬁ  ed-release (MR) prednisone group and 6.7 mg for immediate-release 
(IR) prednisone group.
‡Three patients added a DMARD during the open-label extension, increasing this 
number to 241 (96.8%).
DAS28, Disease Activity Score of 28 joints; DMARDs, disease-modifying antirheumatic 
drugs; HAQ-DI, Health Assessment Questionnaire Disability Index; MS, morning 
stiffness of the joints; N, number of subjects enrolled; n, number of available 
observations; RA, rheumatoid arthritis; VAS, visual analogue scale.
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therapy. The use of speciﬁ  c DMARDs in the two study phases 
was therefore similar.
Morning stiffness
The course of the relative changes in the duration of MS from 
baseline is shown in ﬁ  gure 2. Owing to the different treatments 
during the double-blind phase, the MR/MR group started the 
open phase with MS −34.5% from baseline and the IR/MR 
patients with MS −1.4%. Two patients who completed the 
double-blind phase did not enter the extension study, so data at 
the end of the double-blind phase and the start of the open-label 
extension are slightly different. When the ﬁ  rst assessments were 
made after 3 months of open-label treatment, MS was reduced 
from baseline by 56% in MR/MR patients and by 54% in IR/
MR patients. The reduction in MS was sustained throughout the 
entire study period. The reduction in MS corresponded to 49% 
(IR/MR group) and 61% (MR/MR group) at 9 months and 45% 
(IR/MR group) and 55% (MR/MR group) at 12 months.
The mean (SD) observed absolute reduction in MS was 88 
(128.3) min in the IR/MR group from a baseline value of 182 
(127.4) min. The mean (SD) absolute reduction in MS in the 
MR/MR group was 83 (83.7) min from a baseline value of 
156 (97.3) min. At the end of the 12-month study, 17% of 
the patients no longer reported MS. The number of patients 
with duration of MS <1 h increased from 10% at screening 
(before the start of the double-blind phase on IR prednisone) 
to 29% at the end of the entire study (on MR prednisone). 
Accordingly, the number of patients with a longer duration of 
MS (≥1 h to <3 h and ≥3 h) decreased from 46% to 26% and 
from 33% to 10% at study completion.
Secondary variables
In the double-blind study the concentrations of IL-6 were almost 
halved by MR prednisone whereas no changes were observed 
in the IR group.5 The same reduction by about 50% was seen 
at the end of the study in the IR/MR patients (from baseline 
1110 IU/l to 515 IU/l, median values). Low levels of IL-6 were 
sustained, but no further reduction was observed in the MR/MR 
group (median 470 IU/l; table 2).
DAS28 and pain showed clinically relevant improvements 
with no differences between the treatment groups (table 2). 
More favourable results were also seen in the patients’ and phy-
sicians’ global assessments of disease activity. Overall, increases 
in the percentage of patients with mild disease activity (from 
9% to 40%) and a decrease in patients with moderate disease 
activity (from 71% to 52%) were seen from baseline to study 
end. At the start of the double-blind phase 19% of patients had 
severe disease activity which was reduced to 7% at 12 months.
Of the 219 patients who completed the entire study, 37% 
achieved an ACR20 response.
Safety
The median duration of exposure to MR prednisone in the open-
label phase was 281 days (range 56–406) and the mean dose was 
6.8 mg/day (median 6.4; range 1.9–21.9). The latter takes into 
account any changes in therapy (eg, temporary interruptions in 
therapy, dose reductions for reduced disease activity and inter-
mittent dose increases to control ﬂ  ares). Although dose changes 
were permitted during the open-label extension, no important 
changes in the ‘stable’ doses were recorded.
Thirty patients (12%) discontinued treatment during the 
open-label extension (ﬁ  gure 2B). Twelve patients discontinued 
for AEs. The most frequent reason for discontinuation was RA 
exacerbation in six patients. This was reported as an AE in both 
study phases. Other medical reasons for discontinuation were 
infection (n=5), gastrointestinal tract disorders (n=3) and preg-
nancy (n=2). The gastrointestinal events were judged by inves-
tigators to be possibly related to prednisone, although all three 
patients were also receiving DMARDs and NSAIDs.
A total of 51 serious AEs were reported by 33 patients. Only 
two of these events (gastric ulcer perforation and gastrointesti-
nal haemorrhage) were judged by investigators to be possibly 
Table 2  Summary of secondary efﬁ  cacy results‡
Median (range) IL-6 (IU/l) Mean (SD) pain VAS (mm)  Mean (SD) DAS 28
Baseline MR IR MR IR MR IR
Start DB† (N=288) 860 (200–23000) 1110 (200–20800) 51 (15) 52 (17) 5.8 (0.8) 5.9 (0.9)
n=142 n=142 n=141 n=143 n=144 n=142
  MR/MR IR/MR MR/MR IR/MR MR/MR IR/MR
End OP (N=219) 470* (200–18300) 515* (200–8100) 40* (26) 39* (24) 4.8* (1.3) 4.9* (1.2)
n=103 n=114 n=98 n=107 n=103 n=115
*As a non-parametric approach for the paired samples, Wilcoxon signed rank tests were applied to the absolute changes from 
baseline of the double-blind phase (p<0.05).
†These data are from the double-blind phase.
‡Descriptive p values are given for the absolute changes from the baseline double-blind phase for available pairs of data.
DAS 28, disease activity score of 28 joints; DB, double-blind study phase; IL-6, interleukin 6; IR, immediate-release; MR, modiﬁ  ed-
release; n, number of available data; N, number of patients enrolled; OP, open-label extension phase; VAS, visual analogue scale.
Figure 2  Duration of morning stiffness during both study phases. 
Course of relative changes in duration of morning stiffness for the 288 
patients starting the double-blind phase and the 249 starting the open 
phase after 3 months of double-blind treatments (n=number of available 
data for baseline (129/125) and end of double-blind phase (111/100), at 
start of open phase (112/101) and at 6 (95/86), 9 (104/88), 12 months 
(97/86) for patients in IR and MR groups. DB, double-blind study phase; 
IR, immediate-release; MR, modiﬁ  ed-release.
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related to study medication. However, both patients were also 
taking DMARDs and NSAIDs. Bone fractures occurred in three 
patients and tendon rupture in one. These events were not caus-
ally attributed to prednisone by the investigators. The other 
serious AEs reported, including gynaecological problems, car-
diovascular diseases, respiratory diseases, joint replacement sur-
gery and synovectomy, were consistent with medical conditions 
expected for this patient population.
AEs were observed in 51% of the patients. The most frequent 
events were RA-related symptoms (14.5%), upper respiratory 
tract infections (2.8%), back pain (2.8%) and weight increase 
(2.8%). AEs rated as being possibly related to study medication 
and observed at a frequency of >1.0% in the total study popu-
lation were upper abdominal pain (n=3, 1.2%), gastritis (n=4, 
1.6%) and weight increase (n=6, 2.4%). AEs indicative of aggra-
vated hypothalamic-pituitary-adrenal (HPA) axis suppression 
were not observed.
DISCUSSION
This study investigated the effects of switching from standard 
prednisone therapy to prednisone chronotherapy with MR pred-
nisone in patients with active RA over a period of 12 months. In 
the double-blind phase of the study, MR prednisone was found 
to produce a signiﬁ  cantly greater reduction in the duration of 
MS than IR prednisone and a signiﬁ  cant reduction in IL-6 lev-
els.5 The reduction in MS duration and IL-6 levels established 
during the double-blind phase in the MR group (MR/MR) was 
found to be sustained during treatment with MR prednisone for 
up to 12 months. Similar improvements were also evident in 
patients switched to MR prednisone in the open-label extension. 
Clinically relevant improvements in disease activity (DAS28) 
and pain intensity (VAS) were also observed over the 12 months. 
The results of our study thus demonstrate that the efﬁ  cacy of 
GC therapy can be improved by administration as chronother-
apy—that is, targeting drug release to the circadian rhythm of 
the underlying inﬂ  ammation and resulting symptoms. This is an 
important observation given the widespread clinical use of GCs 
in the treatment of RA and other rheumatic diseases.
It is encouraging to see that 37% of the patients reached an 
ACR20 improvement at the end of the study despite long-term 
GC pretreatment and longstanding disease. This is of special 
importance because, with a disease history of ≥10 years as seen 
in our patients, pain and other symptoms are not only caused by 
inﬂ  ammation but also, at least in part, by irreversible damage to 
the synovium, cartilage and bone. Nevertheless, MR prednisone 
with its convenient night-time administration regimen success-
fully reduces the inﬂ  ammatory component in a unique way.
The results of this study also further conﬁ  rm the low level 
of clinically relevant AEs associated with low-dose GC therapy 
and are in agreement with published reviews.13 14 MR predni-
sone was found to have a similar safety proﬁ  le to IR prednisone 
given at the same dosages. In particular, no signs or symptoms 
were noted that might indicate aggravation of suppression of 
the HPA axis. Indeed, a study of HPA axis function in a subgroup 
of patients from this study reported elsewhere15 found that: (1) 
cortisol levels immediately before and after stimulation were 
comparable between treatments and (2) there was no evidence 
of greater suppression of the HPA axis during treatment with 
MR prednisone for up to 12 months. Given the superior efﬁ  cacy 
reported from the double-blind study for MR prednisone over 
IR prednisone and the similar safety proﬁ  le, MR prednisone can 
thus be expected to have an improved beneﬁ  t to risk ratio over 
IR prednisone.
A potential limitation of the study is that it involved two differ-
ently designed phases: an initial blinded active controlled phase 
followed by an uncontrolled open-label extension. Therefore, 
only descriptive statistical methods could be employed to ana-
lyse data from the open-label extension. However, the IR pred-
nisone group showed comparable effects when switched to MR 
prednisone chronotherapy, thereby conﬁ  rming the robustness 
of the observed treatment effects.
In conclusion, the results of the completed CAPRA1 study 
reported here suggest that low-dose MR prednisone chronother-
apy offers signiﬁ  cant beneﬁ  ts over IR prednisone for the treat-
ment of RA which are maintained for up to 12 months. Further 
studies are warranted to investigate the beneﬁ  t of low-dose MR 
  prednisone chronotherapy in both GC-naïve patients with early 
RA and those with other inﬂ  ammatory conditions. Indeed, chro-
notherapy may well offer signiﬁ  cant advantages over standard 
therapies in diseases such as polymyalgia rheumatica16 17 and 
asthma.
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